Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma
Adeel R. Seyal, Fernanda D. Gonzalez‐Guindalini, Atilla Arslanoglu, Carla B. Harmath, Robert J. Lewandowski, Riad Salem, Vahid Yaghmai – 22 May 2015 – The purpose of our study was to evaluate the reproducibility of Modified Response Evaluation Criteria in Solid Tumors (mRECIST) in hepatocellular carcinoma (HCC) lesions undergoing transarterial radioembolization (TARE) therapy and to determine whether mRECIST reproducibility is affected by the enhancement pattern of HCC. One hundred and three HCC lesions from 103 patients treated with TARE were evaluated.